HRP20250425T1 - Modulatori somatostatina i njihove uporabe - Google Patents
Modulatori somatostatina i njihove uporabe Download PDFInfo
- Publication number
- HRP20250425T1 HRP20250425T1 HRP20250425TT HRP20250425T HRP20250425T1 HR P20250425 T1 HRP20250425 T1 HR P20250425T1 HR P20250425T T HRP20250425T T HR P20250425TT HR P20250425 T HRP20250425 T HR P20250425T HR P20250425 T1 HRP20250425 T1 HR P20250425T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- pharmaceutically acceptable
- c4alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732735P | 2018-09-18 | 2018-09-18 | |
| EP19863395.0A EP3853218B1 (en) | 2018-09-18 | 2019-09-17 | Somatostatin modulators and uses thereof |
| PCT/US2019/051514 WO2020061046A1 (en) | 2018-09-18 | 2019-09-17 | Somatostatin modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250425T1 true HRP20250425T1 (hr) | 2025-06-20 |
Family
ID=69772634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250425TT HRP20250425T1 (hr) | 2018-09-18 | 2019-09-17 | Modulatori somatostatina i njihove uporabe |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10696689B2 (https=) |
| EP (2) | EP3853218B1 (https=) |
| JP (1) | JP7431813B2 (https=) |
| AR (1) | AR116424A1 (https=) |
| DK (1) | DK3853218T3 (https=) |
| ES (1) | ES3022912T3 (https=) |
| FI (1) | FI3853218T3 (https=) |
| HR (1) | HRP20250425T1 (https=) |
| HU (1) | HUE071203T2 (https=) |
| LT (1) | LT3853218T (https=) |
| PL (1) | PL3853218T3 (https=) |
| PT (1) | PT3853218T (https=) |
| RS (1) | RS66720B1 (https=) |
| SI (1) | SI3853218T1 (https=) |
| SM (1) | SMT202500155T1 (https=) |
| TW (1) | TWI852944B (https=) |
| WO (1) | WO2020061046A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221279T1 (hr) | 2016-07-14 | 2022-12-23 | Crinetics Pharmaceuticals, Inc. | Modulatori somatostatina i njihove uporabe |
| WO2018170284A1 (en) | 2017-03-16 | 2018-09-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| EP3752498B1 (en) | 2018-02-12 | 2023-06-28 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| AR116424A1 (es) | 2018-09-18 | 2021-05-05 | Crinetics Pharmaceuticals Inc | Moduladores de la somatostatina y usos de los mismos |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| FI4210700T3 (fi) | 2020-09-09 | 2025-09-16 | Crinetics Pharmaceuticals Inc | Somatostatiinimodulaatorin formulaatioita |
| EP4294797A1 (en) * | 2021-02-17 | 2023-12-27 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of a somatostatin modulator |
| JP2026500913A (ja) | 2022-12-13 | 2026-01-09 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンサブタイプ－２受容体（ｓｓｔ２ｒ）標的化治療薬及びその使用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127343A (en) * | 1996-05-14 | 2000-10-03 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| CA2644929A1 (en) | 2006-03-13 | 2008-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| EP2054385A2 (en) | 2006-08-15 | 2009-05-06 | F. Hoffmann-Roche AG | Phenyl, pyridine and quinoline derivatives |
| EP2211619A1 (en) | 2007-10-18 | 2010-08-04 | Merck Sharp & Dohme Corp. | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| CA2729220A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | Di-substituted phenyl compounds |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| CA2772194A1 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
| CA2799414A1 (en) * | 2010-05-18 | 2011-11-24 | Merck Sharp & Dohme Corp. | Spiro isoxazoline compounds as sstr5 antagonists |
| GB201008290D0 (en) | 2010-05-18 | 2010-06-30 | Syngenta Ltd | Chemical compounds |
| WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| AU2014325078B2 (en) | 2013-09-30 | 2018-10-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity to somatostatin receptor and medicinal use thereof |
| CN105579524B (zh) | 2013-10-02 | 2018-05-04 | 株式会社可乐丽 | 树脂组合物、多层片、包装材料和容器 |
| HRP20221279T1 (hr) | 2016-07-14 | 2022-12-23 | Crinetics Pharmaceuticals, Inc. | Modulatori somatostatina i njihove uporabe |
| JP6838387B2 (ja) * | 2016-12-21 | 2021-03-03 | トヨタ紡織株式会社 | 内装部品の取付構造 |
| CN110300749A (zh) | 2017-02-08 | 2019-10-01 | 小野药品工业株式会社 | 具有生长抑素受体激动活性的化合物及其医药用途 |
| WO2018170284A1 (en) | 2017-03-16 | 2018-09-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| EP3752498B1 (en) | 2018-02-12 | 2023-06-28 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| AR116424A1 (es) | 2018-09-18 | 2021-05-05 | Crinetics Pharmaceuticals Inc | Moduladores de la somatostatina y usos de los mismos |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
-
2019
- 2019-09-17 AR ARP190102640A patent/AR116424A1/es unknown
- 2019-09-17 PT PT198633950T patent/PT3853218T/pt unknown
- 2019-09-17 WO PCT/US2019/051514 patent/WO2020061046A1/en not_active Ceased
- 2019-09-17 RS RS20250348A patent/RS66720B1/sr unknown
- 2019-09-17 HU HUE19863395A patent/HUE071203T2/hu unknown
- 2019-09-17 DK DK19863395.0T patent/DK3853218T3/da active
- 2019-09-17 JP JP2021514532A patent/JP7431813B2/ja active Active
- 2019-09-17 EP EP19863395.0A patent/EP3853218B1/en active Active
- 2019-09-17 HR HRP20250425TT patent/HRP20250425T1/hr unknown
- 2019-09-17 LT LTEPPCT/US2019/051514T patent/LT3853218T/lt unknown
- 2019-09-17 EP EP25151398.2A patent/EP4548974A3/en active Pending
- 2019-09-17 US US16/572,921 patent/US10696689B2/en active Active
- 2019-09-17 ES ES19863395T patent/ES3022912T3/es active Active
- 2019-09-17 FI FIEP19863395.0T patent/FI3853218T3/fi active
- 2019-09-17 TW TW108133468A patent/TWI852944B/zh active
- 2019-09-17 PL PL19863395.0T patent/PL3853218T3/pl unknown
- 2019-09-17 SI SI201930927T patent/SI3853218T1/sl unknown
- 2019-09-17 SM SM20250155T patent/SMT202500155T1/it unknown
-
2020
- 2020-05-19 US US16/877,947 patent/US11186590B2/en active Active
-
2021
- 2021-10-26 US US17/511,326 patent/US20220048924A1/en not_active Abandoned
-
2022
- 2022-04-06 US US17/714,825 patent/US11834462B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7431813B2 (ja) | 2024-02-15 |
| LT3853218T (lt) | 2025-05-12 |
| US20220048924A1 (en) | 2022-02-17 |
| US11186590B2 (en) | 2021-11-30 |
| JP2022501342A (ja) | 2022-01-06 |
| TW202024095A (zh) | 2020-07-01 |
| ES3022912T3 (en) | 2025-05-29 |
| US20230022513A1 (en) | 2023-01-26 |
| US11834462B2 (en) | 2023-12-05 |
| HUE071203T2 (hu) | 2025-08-28 |
| AR116424A1 (es) | 2021-05-05 |
| PL3853218T3 (pl) | 2025-06-02 |
| SMT202500155T1 (it) | 2025-05-12 |
| PT3853218T (pt) | 2025-04-02 |
| EP3853218B1 (en) | 2025-02-19 |
| US10696689B2 (en) | 2020-06-30 |
| US20200283453A1 (en) | 2020-09-10 |
| EP3853218A4 (en) | 2022-02-16 |
| DK3853218T3 (da) | 2025-04-22 |
| EP4548974A3 (en) | 2025-08-13 |
| FI3853218T3 (fi) | 2025-04-15 |
| EP3853218A1 (en) | 2021-07-28 |
| US20200087318A1 (en) | 2020-03-19 |
| SI3853218T1 (sl) | 2025-06-30 |
| EP4548974A2 (en) | 2025-05-07 |
| WO2020061046A1 (en) | 2020-03-26 |
| TWI852944B (zh) | 2024-08-21 |
| RS66720B1 (sr) | 2025-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250425T1 (hr) | Modulatori somatostatina i njihove uporabe | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20210291T1 (hr) | Imunoregulatorna sredstva | |
| RU2009127095A (ru) | Новые оксадиазольные соединения | |
| HRP20251220T1 (hr) | Derivati bipirazola kao jak inhibitori | |
| AR098991A1 (es) | Compuestos de nicotinamida sustituida con heteroarilo | |
| RU2012132527A (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ, ИХ СОДЕРЖАЩАЯ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С КИНАЗОЙ mTOR ИЛИ КИНАЗОЙ PI3K | |
| HRP20201304T1 (hr) | Spoj derivata 1,3,4-oksadiazol-amida koji služi kao inhibitor histonske deacetilaze 6 i farmaceutski pripravak koji sadrži taj spoj | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| HRP20170103T1 (hr) | Triazolopiridazini kao modulatori tirozin kinaze | |
| HRP20191901T1 (hr) | Ciklizirani derivati sulfamoilarilamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| RU2017122364A (ru) | N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина | |
| HRP20140950T1 (hr) | Novi spojevi i pripravci, te postupci njihove primjene | |
| RU2012110246A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| HRP20100607T1 (hr) | Spojevi piperidinilamino-tieno(2,3-d) pirimidina | |
| HRP20191579T1 (hr) | Spojevi kao modulatori za ror gama | |
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| HRP20120735T1 (hr) | Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora | |
| HRP20171873T1 (hr) | Fluorinirani antagonisti integrina | |
| HRP20211801T1 (hr) | Derivati kinolin-2-ona | |
| HRP20220781T1 (hr) | Derivati 2,4-diaminokinazolina i njihova upotreba u liječenju virusnih infekcija, raka ili alergija | |
| JP2022501342A5 (https=) | ||
| HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa |